Contrasts between mucormycosis and aspergillosis in oncohematological patients.

In retrospective multicenter study from years 2007-2017, we evaluated 59 oncohematological patients with mucormycosis and 541 with invasive aspergillosis (IA). Mucormycosis developed more often in children and adolescents (P = .001), as well as after the emergence of graft versus host disease (P = .0001). Patients with mucormycosis had more severe neutropenia (88% vs 82%), the median duration was 30 versus 14 days (P = .0001) and lymphocytopenia (77% vs 65%), with a median duration (25 vs 14 days, P = .001) as compared to patients with IA. The lung infection was less frequent in patients with mucormycosis than in IA patients (73% vs 97%, P = .02), but more frequent was involvement of 2 or more organs (42% vs 8%, P = .001) and involvement of paranasal sinuses (15% vs 6%, P = .04). Typical clinical features of mucormycosis were localized pain syndrome (53% vs 5%, P = .0001), hemoptysis (32% vs 6%, P = .001), pleural effusion on lung CT scan (53% vs 7%, P = .003), lesions with destruction (38% vs 8%, P = .0001), and a "reverse halo" sign (17% vs 3%). The overall 12-week survival was significantly lower in patients with mucormycosis than for IA patients (49% vs 81%, P = .0001). In both groups unfavorable prognosis factors were ≥2 organs involvement (P = .0009), and concomitant bacterial or viral infection (P = .001, P = .008, respectively). In mucormycosis patients favorable prognosis factor was remission of underlying disease (P = .006).

[1]  F. Bouwman,et al.  Epidemiology of invasive aspergillosis and triazole-resistant Aspergillus fumigatus in patients with haematological malignancies: a single-centre retrospective cohort study , 2018, The Journal of antimicrobial chemotherapy.

[2]  C. Beigelman-Aubry,et al.  Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. , 2018, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[3]  A. Ibrahim,et al.  Challenges in the diagnosis and treatment of mucormycosis. , 2018, Medical mycology.

[4]  S. Park,et al.  Characteristics of culture-positive invasive pulmonary aspergillosis in patients with hematologic diseases , 2017, Medicine.

[5]  Felix Bongomin,et al.  Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision , 2017, Journal of fungi.

[6]  P. Escribano,et al.  Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: Epidemiology and microbiological characterization of the isolates , 2017, PloS one.

[7]  H. Dombret,et al.  Epidemiology of invasive fungal infections during induction therapy in adults with acute lymphoblastic leukemia: a GRAALL-2005 study , 2017, Leukemia & lymphoma.

[8]  R. Mody,et al.  Trends in Hospitalizations Related to Invasive Aspergillosis and Mucormycosis in the United States, 2000–2013 , 2017, Open forum infectious diseases.

[9]  L. Pagano,et al.  ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients , 2016, Haematologica.

[10]  Алексей Сергеевич Колбин,et al.  ИНВАЗИВНЫЙ МУКОРМИКОЗ У ОНКОГЕМАТОЛОГИЧЕСКИХ БОЛЬНЫХ (результаты проспективного исследования) , 2017 .

[11]  Jinlin Song,et al.  Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study , 2016, BMC Infectious Diseases.

[12]  E. Dees,et al.  Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer Institute. , 2016, Journal of the National Cancer Institute.

[13]  J. Baddley,et al.  Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial , 2016, The Lancet.

[14]  D. Denning,et al.  The burden of serious fungal diseases in Russia , 2015, Mycoses.

[15]  Sung‐Han Kim,et al.  Comparison of computed tomographic findings in pulmonary mucormycosis and invasive pulmonary aspergillosis. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[16]  A. Kolbin,et al.  Mucormycosis in haematological patients: case report and results of prospective study in Saint Petersburg, Russia , 2014, Mycoses.

[17]  P. Pagès,et al.  The reversed halo sign: pathognomonic pattern of pulmonary mucormycosis in leukemic patients with neutropenia? , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  Russell E. Lewis,et al.  Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20‐year autopsy study , 2013, Mycoses.

[19]  Kieren A Marr,et al.  Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. , 2012, The Journal of infection.

[20]  R. Takimoto,et al.  Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies , 2012, International Journal of Hematology.

[21]  A. Borkhardt,et al.  Invasive Aspergillosis in Pediatric Oncology Patients: A Rare Event With Poor Prognosis – Case Analysis to Plan Better Targeted Prophylactic or Therapeutic Measurement , 2012, Klinische Pädiatrie.

[22]  C. Elie,et al.  A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  Antoine Duclos,et al.  Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009 , 2011, Haematologica.

[24]  F. Marty,et al.  Mortality in Hematologic Malignancy and Hematopoietic Stem Cell Transplant Patients with Mucormycosis, 2001 to 2009 , 2011, Antimicrobial Agents and Chemotherapy.

[25]  D. Kontoyiannis,et al.  The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  R. Porcher,et al.  High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[27]  Thomas J Walsh,et al.  Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  Giuseppe Leone,et al.  Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study , 2010, Haematologica.

[29]  V. Saegeman,et al.  Epidemiology of mucormycosis: review of 18 cases in a tertiary care hospital. , 2010, Medical mycology.

[30]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.